Comparing Effectiveness of Aripiprazole Augmentation, rTMS Augmentation, and Switching to Venlafaxine XR in Treatment Resistant Depression (ASCERTAIN-TRD)

Comparing Effectiveness of Aripiprazole Augmentation, rTMS Augmentation, and Switching to Venlafaxine XR in Treatment Resistant Depression (ASCERTAIN-TRD)
Recruiting
18 years - 80 years
All
1 Location

Brief description of study

This is a multi-site, randomized, open-label, to compare the efficacy of aripiprazole augmentation, rTMS augmentation, and switching to venlafaxine XR as treatments for treatment-resistant depression.

Detailed description of study

Subjects will be randomized to one of three treatment arms: a) aripiprazole added to the current antidepressant, b) rTMS added to the current antidepressant, and c) switching to venlafaxine XR. All subjects will be followed for 8 weeks to examine the efficacy of the study treatments.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Depression, Major depression, Depression, depression
  • Age: 18 years - 80 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: TX4803

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.